Drugs / LAU-7b
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03265288 | Nov 2018 → Sep 2021 | cystic fibrosis | Laurent Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 2/32 trials · 2 missed | ||||||
| Phase 2/3 | NCT05999435 | Nov 2023 → Aug 2024 | long COVID-19 | Laurent Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 2/3 | NCT04417257 | Aug 2020 → Feb 2024 | COVID-19 | Laurent Pharmaceuticals Inc. | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAU-7b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04417257 ↗ |
| Known as | fenretinide | “Active drug fenretinide (as LAU-7b capsules)” NCT03265288 ↗ |
| Route | Oral | “LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.” NCT03265288 ↗ |